Mekel R C, den Boer D J
S Afr Med J. 1985 Sep 14;68(6):385-6.
Forty-three patients with a recently healed duodenal ulcer were entered into a 1-year double-blind trial to evaluate the efficacy and tolerance of ranitidine (Zantac; Glaxo). There were no drop-outs. After 1 year 18 of the 22 patients receiving 150 mg ranitidine at night (82%) and 3 of the 21 receiving placebo (14%) were ulcer- and symptom-free. No drug-related side-effects were noticed. A maintenance dose of ranitidine seems to be a safe and effective means of preventing duodenal ulcer recurrence.
43例近期十二指肠溃疡愈合的患者进入一项为期1年的双盲试验，以评估雷尼替丁（善胃得；葛兰素公司）的疗效和耐受性。无患者退出试验。1年后，夜间服用150毫克雷尼替丁的22例患者中有18例（82%）溃疡愈合且无症状，服用安慰剂的21例患者中有3例（14%）溃疡愈合且无症状。未发现与药物相关的副作用。雷尼替丁维持剂量似乎是预防十二指肠溃疡复发的一种安全有效的方法。
